Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study
暂无分享,去创建一个
G. Lippi | Z. Prohászka | L. Cervenak | E. Favaloro | J. Benoit | T. Masszi | P. Reményi | M. Réti | D. Cooper | P. Kiszel | B. Henry | J. Szlávik | G. Sinkovits | D. Csuka | J. Gal | Z. Förhécz | E. Kajdácsi | S. Benoit | I. Vályi-Nagy | L. Gopcsa | I. Bobek | B. Lakatos | Z. Iványi | Ivan Szergyuk | M. H. S. de Oliveira | N. Pode-Shakked | V. Müller | B. Szathmáry | Z. Prohászka | L. Hurler | B. Mező
[1] P. Boor,et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19 , 2021, Cell.
[2] G. Remuzzi,et al. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study , 2021, PloS one.
[3] Thomas C. Pitts. Soliris to Stop Immune-Mediated Death in COVID-19 (SOLID-C19)—A Compassionate-Use Study of Terminal Complement Blockade in Critically Ill Patients with COVID-19-Related Adult Respiratory Distress Syndrome , 2021, Viruses.
[4] J. Gill,et al. COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy , 2021, Journal of Nephrology.
[5] S. Caillard,et al. COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report , 2021, Journal of Nephrology.
[6] G. Lippi,et al. Complement levels at admission as a reflection of coronavirus disease 2019 (COVID‐19) severity state , 2021, Journal of medical virology.
[7] P. G. Asteris,et al. Genetic justification of severe COVID-19 using a rigorous algorithm , 2021, Clinical Immunology.
[8] S. Tsiftsoglou. SARS-CoV-2 associated Complement genetic variants possibly deregulate the activation of the Alternative pathway affecting the severity of infection , 2021, Molecular Immunology.
[9] Z. Prohászka,et al. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection , 2021, Frontiers in Immunology.
[10] K. Jhaveri,et al. Pathology of COVID-19-associated acute kidney injury , 2021, Clinical kidney journal.
[11] D. Prati,et al. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19 , 2021, Journal of Autoimmunity.
[12] Z. Harel,et al. The Prevalence of Acute Kidney Injury in Patients Hospitalized With COVID-19 Infection: A Systematic Review and Meta-analysis , 2020, Kidney Medicine.
[13] G. Lippi,et al. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID‐19: Evidence of SARS‐CoV‐2 induced secondary thrombotic microangiopathy , 2020, International journal of laboratory hematology.
[14] G. Lippi,et al. The anti-inflammatory cytokine response characterized by elevated interleukin-10 is a stronger predictor of severe disease and poor outcomes than the pro-inflammatory cytokine response in coronavirus disease 2019 (COVID-19) , 2020, Clinical chemistry and laboratory medicine.
[15] Samantha K. Brenner,et al. AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.
[16] Karl Erik Müller,et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients , 2020, Proceedings of the National Academy of Sciences.
[17] G. Lippi,et al. Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis , 2020, Acta bio-medica : Atenei Parmensis.
[18] Benjamin S. Glicksberg,et al. AKI in Hospitalized Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.
[19] John D Lambris,et al. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy , 2020, Clinical Immunology.
[20] G. Lippi,et al. Validation of the Corona-Score for rapid identification of SARS-CoV-2 infections in patients seeking emergency department care in the United States , 2020, Clinical chemistry and laboratory medicine.
[21] Jessica K De Freitas,et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection , 2020, Nature Medicine.
[22] Jing Wang,et al. Identify the Risk Factors of COVID-19-Related Acute Kidney Injury: A Single-Center, Retrospective Cohort Study , 2020, Frontiers in Medicine.
[23] M. Zuckerman,et al. Terminal complement inhibition dampens the inflammation during COVID‐19 , 2020, British journal of haematology.
[24] S. Dabernat,et al. Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019 , 2020, Clinical kidney journal.
[25] G. Remuzzi,et al. The case of complement activation in COVID-19 multiorgan impact , 2020, Kidney International.
[26] John D. Lambris,et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 , 2020, Clinical Immunology.
[27] Giuseppe Lippi,et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis , 2020, Clinica Chimica Acta.
[28] C. Garlanda,et al. Complement as a target in COVID-19? , 2020, Nature Reviews Immunology.
[29] David Berlin,et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.
[30] P. Marchetti,et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. , 2020, European review for medical and pharmacological sciences.
[31] Wei Chen,et al. Extensive Acute Lower Extremity Arterial Thrombosis: A Major Thrombus Formation Caused by COVID-19 , 2020, medRxiv.
[32] J. Kellum,et al. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. , 2020, Critical care clinics.
[33] M. Friedlander. The Triangular Relationship , 2019, Sadat and Begin.
[34] N. Jourde-Chiche,et al. Endothelium structure and function in kidney health and disease , 2019, Nature Reviews Nephrology.
[35] John D Lambris,et al. Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis , 2018, Circulation.
[36] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[37] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[38] G. Pruijn,et al. NETosis, complement, and coagulation: a triangular relationship , 2018, Cellular & Molecular Immunology.
[39] John D. Lambris,et al. Complement in disease: a defence system turning offensive , 2016, Nature Reviews Nephrology.
[40] C. Wang,et al. Neutrophil extracellular traps can activate alternative complement pathways , 2015, Clinical and experimental immunology.
[41] É. Azoulay,et al. Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity , 2015, Journal of thrombosis and haemostasis : JTH.
[42] S. Kaveri,et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. , 2014, Blood.
[43] H. Crijns,et al. Elevated Levels of Circulating DNA and Chromatin Are Independently Associated With Severe Coronary Atherosclerosis and a Prothrombotic State , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[44] B. Lämmle,et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. , 2012, Blood.
[45] A. Khwaja. KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.
[46] D. Wagner,et al. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[47] A. Blom,et al. Neutrophil Extracellular Traps That Are Not Degraded in Systemic Lupus Erythematosus Activate Complement Exacerbating the Disease , 2012, The Journal of Immunology.
[48] Reference Keys , 2012, Kidney international supplements.
[49] Z. Prohászka,et al. Complement activation in thrombotic thrombocytopenic purpura , 2011, Journal of thrombosis and haemostasis : JTH.
[50] Min Chen,et al. ANCA-associated vasculitides—advances in pathogenesis and treatment , 2010, Nature Reviews Rheumatology.
[51] Min Chen,et al. The complement system in systemic autoimmune disease. , 2010, Journal of autoimmunity.
[52] Peter A. Ward,et al. The complement system , 1981, Cell and Tissue Research.
[53] J. Köhl,et al. The role of the anaphylatoxins in health and disease. , 2009, Molecular immunology.
[54] F. Schmidt. Meta-Analysis , 2008 .
[55] J.,et al. Report of Five Cases , 2013 .
[56] D. C. Henckel,et al. Case report. , 1995, Journal.
[57] J. Emile,et al. An ELISA technique for the measurement of C1q in cerebrospinal fluid. , 1988, Journal of immunological methods.
[58] T. Fetterhoff,et al. A micromodification of the CH50 test for the classical pathway of complement. , 1984, Journal of clinical & laboratory immunology.
[59] Nitin R. Patel,et al. A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .